董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Bruce T. Bernstein | 男 | Director and Vice-Chairman of the Board | 62 | 56.35万美元 | 3.59 | 2026-03-28 |
| William S. Singer | 男 | Director | 85 | 40.46万美元 | 2.46 | 2026-03-28 |
| Joshua N. Silverman | 男 | Executive Chairman | 55 | 179.51万美元 | 9.26 | 2026-03-28 |
| Robert Ephron | 男 | Director | 55 | 7.46万美元 | 0.45 | 2026-03-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert Weinstein | 男 | Chief Financial Officer and Executive Vice President and Secretary | 66 | 79.31万美元 | 2.00 | 2026-03-28 |
董事简历
中英对照 | 中文 | 英文- Bruce T. Bernstein
-
Bruce T. Bernstein于2020年加入Petros担任董事。Bernstein先生于2016年至2020年担任Neurotrope的董事会成员，目前担任Synaptogenix, Inc.的董事会成员，Synaptogenix, Inc.是Neurotrope的运营子公司，Neurotrope于2020年12月从Neurotrope分拆出来。Bernstein先生在证券行业拥有30多年的经验，主要担任两个另类金融基金的高级投资组合经理，以及套利策略的交易和结构设计。Bernstein先生自2006年起担任Rockmore Capital，LLC的总裁，该公司是一家直接投资和贷款基金的经理，管理的最高资产为1.4亿美元。此前，他曾担任Omicron Capital，LP的联席总裁，该公司是一家位于纽约的投资公司，他于2001年加入该公司。Omicron Capital专注于对上市小型股公司的直接投资和贷款，管理的最高资产为2.6亿美元。在加入Omicron Capital之前，Bernstein先生曾任职于富通投资公司，担任该银行全球证券套利业务部高级副总裁，专门研究股票结构性产品和股票套利，之后担任该银行美国自营投资业务总裁。在加入海富通之前，Bernstein先生是野村证券国际公司股票衍生产品组的主管，专门从事跨境税收套利、国内股票套利和结构性股票互换。Bernstein的职业生涯始于Kidder Peabody，后来升至助理财务主管。Bernstein先生还担任XpresSpa控股公司的董事会成员，该公司是总部设在纽约的世界领先的机场水疗公司。Bernstein先生还是Summit Digital Health的董事会成员，Summit Digital Health是一家总部位于新泽西州的激光血糖监测仪分销商。Bernstein先生拥有纽约城市大学（Baruch）的学士学位。
Bruce T. Bernstein served as a Director for Neurotrope since November 14, 2016 and has been vice chairman of the Board of TAO Synergies since October, 2025. Mr. Bernstein has over thirty years of experience in the securities industry, primarily as senior portfolio manager for two alternative finance funds as well as in trading and structuring of arbitrage strategies. Mr. Bernstein has served as President of Rockmore Capital, LLC since 2006, the manager of a direct investment and lending fund with peak assets under management of $140 million. Previously, he served as Co President of Omicron Capital, LP, an investment firm based in New York, which he joined in 2001. Omicron Capital focused on direct investing and lending to public small cap companies and had peak assets under management of $260 million. Prior to joining Omicron Capital, Mr. Bernstein was with Fortis Investments Inc., where he was Senior Vice President in the bank's Global Securities Arbitrage business unit, specializing in equity structured products and equity arbitrage and then President in charge of the bank's proprietary investment business in the United States. Prior to Fortis, Mr. Bernstein was Director in the Equity Derivatives Group at Nomura Securities International specializing in cross border tax arbitrage, domestic equity arbitrage and structured equity swaps. Mr. Bernstein started his career at Kidder Peabody, where he rose to the level of Assistant Treasurer. Mr. Bernstein also serves as a member of the Board of Directors of XWELL, Inc., the leading airport spa company in the world, based in New York and Petros Pharmaceuticals, Inc. Mr. Bernstein is also a member of the board of Wrap Technologies Inc., a provider of public safety technology and services, based in Florida. Mr. Bernstein holds a B.B.A. from City University of New York (Baruch). - Bruce T. Bernstein于2020年加入Petros担任董事。Bernstein先生于2016年至2020年担任Neurotrope的董事会成员，目前担任Synaptogenix, Inc.的董事会成员，Synaptogenix, Inc.是Neurotrope的运营子公司，Neurotrope于2020年12月从Neurotrope分拆出来。Bernstein先生在证券行业拥有30多年的经验，主要担任两个另类金融基金的高级投资组合经理，以及套利策略的交易和结构设计。Bernstein先生自2006年起担任Rockmore Capital，LLC的总裁，该公司是一家直接投资和贷款基金的经理，管理的最高资产为1.4亿美元。此前，他曾担任Omicron Capital，LP的联席总裁，该公司是一家位于纽约的投资公司，他于2001年加入该公司。Omicron Capital专注于对上市小型股公司的直接投资和贷款，管理的最高资产为2.6亿美元。在加入Omicron Capital之前，Bernstein先生曾任职于富通投资公司，担任该银行全球证券套利业务部高级副总裁，专门研究股票结构性产品和股票套利，之后担任该银行美国自营投资业务总裁。在加入海富通之前，Bernstein先生是野村证券国际公司股票衍生产品组的主管，专门从事跨境税收套利、国内股票套利和结构性股票互换。Bernstein的职业生涯始于Kidder Peabody，后来升至助理财务主管。Bernstein先生还担任XpresSpa控股公司的董事会成员，该公司是总部设在纽约的世界领先的机场水疗公司。Bernstein先生还是Summit Digital Health的董事会成员，Summit Digital Health是一家总部位于新泽西州的激光血糖监测仪分销商。Bernstein先生拥有纽约城市大学（Baruch）的学士学位。
- Bruce T. Bernstein served as a Director for Neurotrope since November 14, 2016 and has been vice chairman of the Board of TAO Synergies since October, 2025. Mr. Bernstein has over thirty years of experience in the securities industry, primarily as senior portfolio manager for two alternative finance funds as well as in trading and structuring of arbitrage strategies. Mr. Bernstein has served as President of Rockmore Capital, LLC since 2006, the manager of a direct investment and lending fund with peak assets under management of $140 million. Previously, he served as Co President of Omicron Capital, LP, an investment firm based in New York, which he joined in 2001. Omicron Capital focused on direct investing and lending to public small cap companies and had peak assets under management of $260 million. Prior to joining Omicron Capital, Mr. Bernstein was with Fortis Investments Inc., where he was Senior Vice President in the bank's Global Securities Arbitrage business unit, specializing in equity structured products and equity arbitrage and then President in charge of the bank's proprietary investment business in the United States. Prior to Fortis, Mr. Bernstein was Director in the Equity Derivatives Group at Nomura Securities International specializing in cross border tax arbitrage, domestic equity arbitrage and structured equity swaps. Mr. Bernstein started his career at Kidder Peabody, where he rose to the level of Assistant Treasurer. Mr. Bernstein also serves as a member of the Board of Directors of XWELL, Inc., the leading airport spa company in the world, based in New York and Petros Pharmaceuticals, Inc. Mr. Bernstein is also a member of the board of Wrap Technologies Inc., a provider of public safety technology and services, based in Florida. Mr. Bernstein holds a B.B.A. from City University of New York (Baruch).
- William S. Singer
-
WilliamS.Singer曾担任CRE总裁至2016年4月26日，并担任其董事会成员。他曾担任律师事务所Kirkland&Ellis LLP的芝加哥办事处的合伙人（从1980年到2006年），也曾一直担任该公司的法律顾问，专注于公司、房地产和立法事务。他曾于2000年、2001年、2002年、2003年和2004年在Crain&8217；s Who&8217；s Who in Chicago Business中任职。Singer先生一直活跃在芝加哥公共服务领域，担任了几年的市议员，并作为市长办公室的候选人。
William S. Singer served as a Director and Vice Chairman of the Board for Neurotrope since August 23, 2019. He was a partner in the Chicago office of the law firm of Kirkland & Ellis LLP from 1980 until 2006 and has been of counsel to that firm since that time, concentrating his practice on corporate, real estate, and legislative matters. Mr. Singer currently serves on the Board of Directors of the National Park Foundation. He was appointed by the Secretary of the Interior. Mr. Singer has been prominently active in Chicago public service, serving as an Alderman for several years and as a candidate for Mayor. - WilliamS.Singer曾担任CRE总裁至2016年4月26日，并担任其董事会成员。他曾担任律师事务所Kirkland&Ellis LLP的芝加哥办事处的合伙人（从1980年到2006年），也曾一直担任该公司的法律顾问，专注于公司、房地产和立法事务。他曾于2000年、2001年、2002年、2003年和2004年在Crain&8217；s Who&8217；s Who in Chicago Business中任职。Singer先生一直活跃在芝加哥公共服务领域，担任了几年的市议员，并作为市长办公室的候选人。
- William S. Singer served as a Director and Vice Chairman of the Board for Neurotrope since August 23, 2019. He was a partner in the Chicago office of the law firm of Kirkland & Ellis LLP from 1980 until 2006 and has been of counsel to that firm since that time, concentrating his practice on corporate, real estate, and legislative matters. Mr. Singer currently serves on the Board of Directors of the National Park Foundation. He was appointed by the Secretary of the Interior. Mr. Singer has been prominently active in Chicago public service, serving as an Alderman for several years and as a candidate for Mayor.
- Joshua N. Silverman
-
Joshua N. Silverman，自2020年5月28日起担任Stablex Technologies，Inc.董事，目前担任Stablex Technologies，Inc.执行董事长兼首席执行官。在2023年12月13日被任命担任这些职位之前，Silverman先生曾担任董事会主席。在合并之前，Silverman先生自2018年合并（定义见下文）以来一直担任DropCar董事会成员。Silverman先生目前担任Parkfield Funding LLC的管理成员。Silverman先生是投资咨询公司Iroquois Capital Management，LLC（“Iroquois”）的联合创始人，之前是其负责人和管理合伙人。从2003年成立到2016年7月，Silverman先生担任Iroquois的联席首席投资官。在Iroquois任职期间，他设计并执行了复杂的交易，构建和谈判对公共和私营公司的投资，并经常被这类公司要求解决与公司结构、现金流和管理相关的低效率问题。2000年至2003年，Silverman先生担任商业银行Vertical Ventures，LLC的联席首席投资官。在组建Iroquois之前，Silverman先生是专门从事并购的精品咨询公司Joele Frank的董事。此前，Silverman曾担任美国总统助理新闻秘书。Silverman先生目前担任MYMD Pharmaceuticals，Inc.（NASDAQ：MYMD）、Pharmacyte，Inc.（NASDAQ：PMCB）、Synaptogenix, Inc.TERM3（NASDAQ：SNPX）和Petros Pharmaceutical，Inc.（NASDAQ：PTPI）的董事，这些公司均为上市公司。他此前于2014年7月至2016年8月担任国家控股公司董事，并于2016年8月至2018年10月担任Marker Therapeutics公司董事。Silverman先生于1992年获得了Lehigh大学的学士学位。
Joshua N. Silverman has served as a director of the Company since August 2022 and as Pharmacyte Biotech, Inc.'s Chief Executive Officer, President and Chairman of the Board since October 2022. Mr. Silverman has served as the managing member of Parkfield Funding LLC since August 2016. Mr. Silverman co founded Iroquois Capital Management, LLC ("Iroquois"), an investment advisory firm, in 2003 and served as its principal, managing partner and co chief investment officer until July 2016. While at Iroquois, he designed and executed complex transactions, structuring and negotiating investments in both public and private companies and has often been called upon by the companies solve inefficiencies as they relate to corporate structure, cash flow, and management. From 2000 to 2003, Mr. Silverman served as co chief investment officer of Vertical Ventures, LLC, a merchant bank. Prior to forming Iroquois, Mr. Silverman was a director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions. Previously, Mr. Silverman served as assistant press secretary to the president of the U.S. Mr. Silverman currently serves as an Executive Chairman of Fabric AI, Inc., (Nasdaq: FABC), Q/C Technologies, Inc. (Nasdaq: QCLS), TAO Synergies Inc. (Nasdaq: TAOX) and Petros Pharmaceutical, Inc. (OTC: PTPI). He previously served as a director of Protagenic Therapeutics, Inc. (Nasdaq: PTIX) from 2016 to 2022. Mr. Silverman received his B.A. from Lehigh University in 1992. - Joshua N. Silverman，自2020年5月28日起担任Stablex Technologies，Inc.董事，目前担任Stablex Technologies，Inc.执行董事长兼首席执行官。在2023年12月13日被任命担任这些职位之前，Silverman先生曾担任董事会主席。在合并之前，Silverman先生自2018年合并（定义见下文）以来一直担任DropCar董事会成员。Silverman先生目前担任Parkfield Funding LLC的管理成员。Silverman先生是投资咨询公司Iroquois Capital Management，LLC（“Iroquois”）的联合创始人，之前是其负责人和管理合伙人。从2003年成立到2016年7月，Silverman先生担任Iroquois的联席首席投资官。在Iroquois任职期间，他设计并执行了复杂的交易，构建和谈判对公共和私营公司的投资，并经常被这类公司要求解决与公司结构、现金流和管理相关的低效率问题。2000年至2003年，Silverman先生担任商业银行Vertical Ventures，LLC的联席首席投资官。在组建Iroquois之前，Silverman先生是专门从事并购的精品咨询公司Joele Frank的董事。此前，Silverman曾担任美国总统助理新闻秘书。Silverman先生目前担任MYMD Pharmaceuticals，Inc.（NASDAQ：MYMD）、Pharmacyte，Inc.（NASDAQ：PMCB）、Synaptogenix, Inc.TERM3（NASDAQ：SNPX）和Petros Pharmaceutical，Inc.（NASDAQ：PTPI）的董事，这些公司均为上市公司。他此前于2014年7月至2016年8月担任国家控股公司董事，并于2016年8月至2018年10月担任Marker Therapeutics公司董事。Silverman先生于1992年获得了Lehigh大学的学士学位。
- Joshua N. Silverman has served as a director of the Company since August 2022 and as Pharmacyte Biotech, Inc.'s Chief Executive Officer, President and Chairman of the Board since October 2022. Mr. Silverman has served as the managing member of Parkfield Funding LLC since August 2016. Mr. Silverman co founded Iroquois Capital Management, LLC ("Iroquois"), an investment advisory firm, in 2003 and served as its principal, managing partner and co chief investment officer until July 2016. While at Iroquois, he designed and executed complex transactions, structuring and negotiating investments in both public and private companies and has often been called upon by the companies solve inefficiencies as they relate to corporate structure, cash flow, and management. From 2000 to 2003, Mr. Silverman served as co chief investment officer of Vertical Ventures, LLC, a merchant bank. Prior to forming Iroquois, Mr. Silverman was a director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions. Previously, Mr. Silverman served as assistant press secretary to the president of the U.S. Mr. Silverman currently serves as an Executive Chairman of Fabric AI, Inc., (Nasdaq: FABC), Q/C Technologies, Inc. (Nasdaq: QCLS), TAO Synergies Inc. (Nasdaq: TAOX) and Petros Pharmaceutical, Inc. (OTC: PTPI). He previously served as a director of Protagenic Therapeutics, Inc. (Nasdaq: PTIX) from 2016 to 2022. Mr. Silverman received his B.A. from Lehigh University in 1992.
- Robert Ephron
-
Robert Ephron，从JK Polk Holdings加入公司，自2024年以来，他一直担任广告和销售方面的顾问。Ephron先生曾于2017年至2023年在派拉蒙担任广告和销售副总裁，并于2015年至2017年在维亚康姆担任广告和销售副总裁。Ephron先生获得了丹佛大学的理学学士学位。
Robert Ephron was appointed to join the Board on August 29, 2025. Mr. Ephron has served as an advisor in advertising and sales at JK Polk Holdings since 2024. He was previously vice president of advertising and sales at Paramount from 2017 to 2023 and vice president of advertising and sales at Viacom from 2015 to 2017. Mr. Ephron served as vice president and director of Viacom from 2004 to 2015, and was an executive director in International Ad Sales at NewsCorp from 1999 to 2004. Prior to his time at NewsCorp, Mr. Ephron worked as an account executive in Ad Sales at Turner Broadcasting from 1994 to 1999. Mr. Ephron received his Bachelor of Science from the University of Denver. - Robert Ephron，从JK Polk Holdings加入公司，自2024年以来，他一直担任广告和销售方面的顾问。Ephron先生曾于2017年至2023年在派拉蒙担任广告和销售副总裁，并于2015年至2017年在维亚康姆担任广告和销售副总裁。Ephron先生获得了丹佛大学的理学学士学位。
- Robert Ephron was appointed to join the Board on August 29, 2025. Mr. Ephron has served as an advisor in advertising and sales at JK Polk Holdings since 2024. He was previously vice president of advertising and sales at Paramount from 2017 to 2023 and vice president of advertising and sales at Viacom from 2015 to 2017. Mr. Ephron served as vice president and director of Viacom from 2004 to 2015, and was an executive director in International Ad Sales at NewsCorp from 1999 to 2004. Prior to his time at NewsCorp, Mr. Ephron worked as an account executive in Ad Sales at Turner Broadcasting from 1994 to 1999. Mr. Ephron received his Bachelor of Science from the University of Denver.
高管简历
中英对照 | 中文 | 英文- Robert Weinstein
Robert Weinstein于2020年2月加入我们的董事会。Weinstein先生拥有30多年的丰富会计和财务经验，担任公共会计师、投资银行家、梦百合私募股权基金负责人和首席财务官。自2013年10月以来，韦恩斯坦一直担任生物技术上市公司Neurotrope，Inc.（McKinsey）的首席财务官。2011年9月至2013年9月，韦恩斯坦先生是制药和生物技术行业几家梦百合公司的独立顾问。Weinstein从2010年3月到2011年8月担任Green Energy Management Services Holdings，Inc.（一家上市能源咨询公司）首席财务官。2007年8月至2010年2月，Weinstein先生担任Xcorporeal，Inc.的首席财务官，该公司是一家上市的处于发展阶段的医疗设备公司，于2010年3月出售给Fresenius Medical USA，后者是全球最大的透析设备和服务提供商。Weinstein先生在芝加哥大学商学院（University of Chicago Graduate School of Business）获得金融与国际商务工商管理硕士学位，是一名不活跃的注册会计师，并在纽约州立大学奥尔巴尼分校（State University of New York at Albany）获得会计学学士学位。
Robert Weinstein has served as a director of the Company since November 2022. Mr. Weinstein has served as chief financial officer of TAO Synergies Inc. (formerly Synaptogenix, Inc.) (Nasdaq: TAOX) since October 2013. In addition, Mr. Weinstein performs work as a consultant for Petros Pharmaceuticals, Inc. (Nasdaq: PTPI) and Fabric AI, Inc. (Nasdaq: FABC). He has extensive accounting and finance experience, spanning more than 40 years, as a public accountant, investment banker, healthcare private equity fund principal and chief financial officer. From September 2011 to the present, Mr. Weinstein has also been an independent consultant for several healthcare companies in the pharmaceutical and biotechnology industries. Mr. Weinstein also serves as a member of the Board of Directors of XWELL, Inc. (formerly XpresSpa Group, Inc.) (Nasdaq: XWEL), a health and wellness company whose core assets, XpresSpa and XpresCheck, is a leading airport retailer of spa services and related health and wellness products. Mr. Weinstein received his MBA degree in finance and international business from the University of Chicago Graduate School of Business, is a Certified Public Accountant (inactive), and received his BS degree in accounting from the State University of New York at Albany. Mr. Weinstein was chosen as a director of the Company because of his public company and financial expertise.- Robert Weinstein于2020年2月加入我们的董事会。Weinstein先生拥有30多年的丰富会计和财务经验，担任公共会计师、投资银行家、梦百合私募股权基金负责人和首席财务官。自2013年10月以来，韦恩斯坦一直担任生物技术上市公司Neurotrope，Inc.（McKinsey）的首席财务官。2011年9月至2013年9月，韦恩斯坦先生是制药和生物技术行业几家梦百合公司的独立顾问。Weinstein从2010年3月到2011年8月担任Green Energy Management Services Holdings，Inc.（一家上市能源咨询公司）首席财务官。2007年8月至2010年2月，Weinstein先生担任Xcorporeal，Inc.的首席财务官，该公司是一家上市的处于发展阶段的医疗设备公司，于2010年3月出售给Fresenius Medical USA，后者是全球最大的透析设备和服务提供商。Weinstein先生在芝加哥大学商学院（University of Chicago Graduate School of Business）获得金融与国际商务工商管理硕士学位，是一名不活跃的注册会计师，并在纽约州立大学奥尔巴尼分校（State University of New York at Albany）获得会计学学士学位。
- Robert Weinstein has served as a director of the Company since November 2022. Mr. Weinstein has served as chief financial officer of TAO Synergies Inc. (formerly Synaptogenix, Inc.) (Nasdaq: TAOX) since October 2013. In addition, Mr. Weinstein performs work as a consultant for Petros Pharmaceuticals, Inc. (Nasdaq: PTPI) and Fabric AI, Inc. (Nasdaq: FABC). He has extensive accounting and finance experience, spanning more than 40 years, as a public accountant, investment banker, healthcare private equity fund principal and chief financial officer. From September 2011 to the present, Mr. Weinstein has also been an independent consultant for several healthcare companies in the pharmaceutical and biotechnology industries. Mr. Weinstein also serves as a member of the Board of Directors of XWELL, Inc. (formerly XpresSpa Group, Inc.) (Nasdaq: XWEL), a health and wellness company whose core assets, XpresSpa and XpresCheck, is a leading airport retailer of spa services and related health and wellness products. Mr. Weinstein received his MBA degree in finance and international business from the University of Chicago Graduate School of Business, is a Certified Public Accountant (inactive), and received his BS degree in accounting from the State University of New York at Albany. Mr. Weinstein was chosen as a director of the Company because of his public company and financial expertise.